Actinium Pharmaceuticals’ Technology

Background
Cancer Cell Killing Agents
Comparison of Alpha And Beta Emitters
Components of Immunotherapy
Assembly of Immunotherapeutic Agents

Assembly of Bi-213 based Alpha Particle Immunotherapies
The antibody/chelator complex ensures consistent stability and quality. Shortly before clinical use, a precisely prepared single patient dose of antibody/ chelator complex will be mixed with freshly prepared Bismuth-213 isotope. The Bismuth-213 is easily and rapidly eluted from Actinium-225. In the hospital laboratory, the Actinium-225 is received as a generator and "milked" to obtain the Bismuth-213. The procedure has been developed and is currently being used in the first clinical trial against Acute Myeloid Leukemia at Memorial Sloan Kettering Cancer Center.

< larger view >

Actinium-225 and Bismuth-213 poses virtually no risk to pharmacy personnel since the Alpha particle radiation cannot penetrate the thickness of a pair of disposable plastic gloves. Hence, the facilities and equipment needed for handling alpha particle therapy are minimal compared to other types of radiation used in medical settings.

<BACK TO TOP >